SGYP - Amarin: Rating Sell With $5 Price Target 2-Year Timeframe (70% Downside)
Amarin (AMRN) has been a darling of biotech investors with one of the highest bullish sentiments that I have seen on a stock. I will not go into the details of the background of this stock since I assume that you are familiar with it. Amarin's sole product Vascepa has a proprietary formulation of EPA (a component of fish oil). Vascepa has been in the U.S. market since 2013 to treat increased triglycerides with marginal sales. Sales have been unimpressive.
Amarin stock jumped earlier this year after the REDUCE-IT trial showed 25% reduction